Role of infections

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 87-100

  Rangelov, Kamen ^a   Sethi, Sanjay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Airway colonization; Chronic infection; Infection in COPD; Innate immunity in COPD; New strain exacerbations; Pneumonia and COPD; Vicious circle hypothesis; Virulence factors

Indexed keywords

AIRWAY COLONIZATION; CHRONIC INFECTION; INFECTION IN COPD; INNATE IMMUNITY IN COPD; NEW STRAIN EXACERBATIONS; PNEUMONIA AND COPD; VICIOUS-CIRCLE HYPOTHESIS; VIRULENCE FACTORS;

BACTERIAL INFECTIONS; CHRONIC DISEASE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; VIRUS DISEASES;

EID: 84893501777     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.012     Document Type: Review

References (107)

1. Stuart-Harris C.H., Pownall M., Scothorne C.M., et al. The factor of infection in chronic bronchitis. QJ Med 1953, 22:121-132.
2. Smith C.B., Golden C.A., Kanner R.E., et al. Haemophilus influenzae and Haemophilus parainfluenzae in chronic obstructive pulmonary disease. Lancet 1976, 1:1253-1255.
3. Smith C.B., Golden C., Klauber M.R., et al. Interactions between viruses and bacteria in patients with chronic bronchitis. JInfect Dis 1976, 134:552-561.
4. Gump D.W., Phillips C.A., Forsyth B.R., et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976, 113:465-473.
5. McHardy V.U., Inglis J.M., Calder M.A., et al. Astudy of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980, 74:228-238.
6. Fagon J.Y., Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Semin Respir Infect 1996, 11:109-118.
7. Tager I., Speizer F.E. Role of infection in chronic bronchitis. NEngl J Med 1975, 292:563-571.
8. Smith C.B., Golden C., Kanner R., et al. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980, 121:225-232.
9. Murphy T.F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 146:1067-1083.
10. Fletcher F., Peto R. The natural history of chronic airflow obstruction. Br Med J 1977, 1:1645-1648.
11. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. NEngl J Med 2008, 359:2355-2365.
12. Mohan A., Chandra S., Agarwal D., et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010, 15:536-542.
13. Kherad O., Kaiser L., Bridevaux P.O., et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest 2010, 138:896-904.
14. Mallia P., Message S.D., Gielen V., et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011, 183:734-742.
15. Sethi S., Sethi R., Eschberger K., et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176(4):356-361.
16. Sethi S., Evans N., Grant B.J., et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. NEngl J Med 2002, 347:465-471.
17. Murphy T.F., Brauer A.L., Sethi S., et al. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. JInfect Dis 2007, 195:81-89.
18. Murphy T.F., Brauer A.L., Grant B.J., et al. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005, 172:195-199.
19. Murphy T.F., Brauer A.L., Eschberger K., et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:853-860.
20. Chin C.L., Manzel L.J., Lehman E.E., et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005, 172:85-91.
21. Sethi S., Wrona C., Eschberger K., et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:491-497.
22. Rosell A., Monso E., Soler N., et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005, 165:891-897.
23. Bandi V., Apicella M.A., Mason E., et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001, 164:2114-2119.
24. Garcha D.S., Thurston S.J., Patel A.R., et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012, 67:1075-1080.
25. Papi A., Bellettato C.M., Braccioni F., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173:1114-1121.
26. Wilkinson T.M., Hurst J.R., Perera W.R., et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006, 129:317-324.
27. Mallia P., Footitt J., Sotero R., et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:1117-1124.
28. Avadhanula V., Rodriguez C.A., Devincenzo J.P., et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. JVirol 2006, 80:1629-1636.
29. Sajjan U.S., Jia Y., Newcomb D.C., et al. H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J 2006, 20:2121-2123.
30. Marston B.J., Plouffe J.F., File T.M., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709-1718.
31. Vinogradova Y., Hippisley-Cox J., Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 2009, 59:e329-e338.
32. Naucler P., Darenberg J., Morfeldt E., et al. Contribution of host, bacterial factors and antibiotic treatment to mortality in adult patients with bacteraemic pneumococcal pneumonia. Thorax 2013, 68:571-579.
33. Ishiguro T., Takayanagi N., Yamaguchi S., et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern Med 2013, 52:317-324.
34. Mullerova H., Chigbo C., Hagan G.W., et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012, 106:1124-1133.
35. Merino-Sanchez M., Alfageme-Michavila I., Reyes-Nunez N., et al. Prognosis in patients with pneumonia and chronic obstructive pulmonary disease. Arch Bronconeumol 2005, 41:607-611. [in Spanish].
36. Crisafulli E., Menendez R., Huerta A., et al. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest 2013, 143:1009-1017.
37. Liapikou A., Polverino E., Ewig S., et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012, 39:855-861.
38. Arancibia F., Bauer T.T., Ewig S., et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002, 162:1849-1858.
39. Torres A., Dorca J., Zalacain R., et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996, 154:1456-1461.
40. Rello J., Rodriguez A., Torres A., et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006, 27:1210-1216.
41. Desai H., Richter S., Doern G., et al. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure. COPD 2010, 7:337-344.
42. Restrepo M.I., Mortensen E.M., Pugh J.A., et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006, 28:346-351.
43. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEngl J Med 2007, 356:775-789.
44. Singh S., Loke Y.K. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010, 5:189-195.
45. Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169:219-229.
46. Spencer S., Karner C., Cates C.J., et al. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, (12). CD007033.
47. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
48. Murphy T.F., Brauer A.L., Schiffmacher A.T., et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:266-272.
49. Sethi S., Maloney J., Grove L., et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:991-998.
50. Charlson E.S., Bittinger K., Haas A.R., et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011, 184:957-963.
51. Soler N., Ewig S., Torres A., et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999, 14:1015-1022.
52. Cabrera-Rubio R., Garcia-Nunez M., Seto L., et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. JClin Microbiol 2012, 50:3562-3568.
53. Bresser P., Out T.A., van Alphen L., et al. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:947-952.
54. Banerjee D., Khair O.A., Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004, 23:685-691.
55. Hill A.T., Campbell E.J., Hill S.L., et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000, 109:288-295.
56. Parameswaran G.I., Wrona C.T., Murphy T.F., et al. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009, 9:178.
57. Zhang M., Li Q., Zhang X.Y., et al. Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis 2010, 29:1487-1493.
58. Tumkaya M., Atis S., Ozge C., et al. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med 2007, 101:729-737.
59. Patel I.S., Vlahos I., Wilkinson T.M., et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:400-407.
60. Retamales I., Elliott W.M., Meshi B., et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001, 164:469-473.
61. Falsey A.R., Formica M.A., Hennessey P.A., et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:639-643.
62. Wilkinson T.M., Donaldson G.C., Johnston S.L., et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:871-876.
63. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:2645-2653.
64. Moghaddam S.J., Clement C.G., De la Garza M.M., et al. Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol 2008, 38:629-638.
65. Martinez-Garcia M.A., Soler-Cataluna J.J., Donat-Sanz Y., et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest 2011, 140(5):1130-1137.
66. Verra F., Escudier E., Lebargy F., et al. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med 1995, 151:630-634.
67. Foster W.M., Langenback E.G., Bergofsky E.H. Disassociation in the mucociliary function of central and peripheral airways of asymptomatic smokers. Am Rev Respir Dis 1985, 132:633-639.
68. Koblizek V., Tomsova M., Cermakova E., et al. Impairment of nasal mucociliary clearance in former smokers with stable chronic obstructive pulmonary disease relates to the presence of a chronic bronchitis phenotype. Rhinology 2011, 49:397-406.
69. Smaldone G.C., Foster W.M., O'Riordan T.G., et al. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993, 103:1390-1396.
70. Vastag E., Matthys H., Zsamboki G., et al. Mucociliary clearance in smokers. Eur J Respir Dis 1986, 68:107-113.
71. Wanner A., Salathe M., O'Riordan T.G. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996, 154:1868-1902.
72. Innes A.L., Woodruff P.G., Ferrando R.E., et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006, 130:1102-1108.
73. Ma R., Wang Y., Cheng G., et al. MUC5AC expression up-regulation goblet cell hyperplasia in the airway of patients with chronic obstructive pulmonary disease. Chin Med Sci J 2005, 20:181-184.
74. Ha U., Lim J.H., Jono H., et al. Anovel role for IkappaB kinase (IKK) alpha and IKKbeta in ERK-dependent up-regulation of MUC5AC mucin transcription by Streptococcus pneumoniae. JImmunol 2007, 178:1736-1747.
75. Chen R., Lim J.H., Jono H., et al. Nontypeable Haemophilus influenzae lipoprotein P6 induces MUC5AC mucin transcription via TLR2-TAK1-dependent p38 MAPK-AP1 and IKKbeta-IkappaBalpha-NF-kappaB signaling pathways. Biochem Biophys Res Commun 2004, 324:1087-1094.
76. Polosukhin V.V., Cates J.M., Lawson W.E., et al. Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:317-327.
77. Ganz T. Defensins: antimicrobial peptides of vertebrates. CR Biol 2004, 327:539-549.
78. Parameswaran G.I., Sethi S., Murphy T.F. Effects of bacterial infection on airway antimicrobial peptides and proteins in chronic obstructive pulmonary disease. Chest 2011, 140(3):611-617.
79. Tjabringa G.S., Rabe K.F., Hiemstra P.S. The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung. Pulm Pharmacol Ther 2005, 18:321-327.
80. Dajani R., Zhang Y., Taft P.J., et al. Lysozyme secretion by submucosal glands protects the airway from bacterial infection. Am J Respir Cell Mol Biol 2005, 32:548-552.
81. Ellison R.T., Giehl T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. JClin Invest 1991, 88:1080-1091.
82. Fitch P.M., Roghanian A., Howie S.E., et al. Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochem Soc Trans 2006, 34:279-282.
83. Crouch E.C. Structure, biologic properties, and expression of surfactant protein D (SP-D). Biochim Biophys Acta 1998, 1408:278-289.
84. Taylor D., Cripps A., Clancy R. Apossible role for lysozyme in determining acute exacerbation in chronic bronchitis. Clin Exp Immunol 1995, 102:406-416.
85. Gompertz S., Bayley D.L., Hill S.L., et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001, 56:36-41.
86. Yang I.A., Seeney S.L., Wolter J.M., et al. Mannose-binding lectin gene polymorphism predicts hospital admissions for COPD infections. Genes Immun 2003, 4:269-274.
87. Betsuyaku T., Kuroki Y., Nagai K., et al. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J 2004, 24:964-970.
88. Honda Y., Takahashi H., Kuroki Y., et al. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996, 109:1006-1009.
89. Tsoumakidou M., Bouloukaki I., Thimaki K., et al. Innate immunity proteins in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Exp Lung Res 2010, 36:373-380.
90. Pace E., Ferraro M., Minervini M.I., et al. Beta defensin-2 is reduced in central but not in distal airways of smoker COPD patients. PLoS One 2012, 7:e33601.
91. Berenson C.S., Kruzel R.L., Eberhardt E., et al. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. JInfect Dis 2013, [Epub ahead of print].
92. Hodge S., Hodge G., Ahern J., et al. Smoking altersalveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007, 37:748-755.
93. Berenson C.S., Garlipp M.A., Grove L.J., et al. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. JInfect Dis 2006, 194:1375-1384.
94. Berenson C.S., Wrona C.T., Grove L.J., et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med 2006, 174:31-40.
95. Oliver B.G., Lim S., Wark P., et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 2008, 63:519-525.
96. Droemann D., Goldmann T., Tiedje T., et al. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005, 6:68.
97. Harvey C.J., Thimmulappa R.K., Sethi S., et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 2011, 3:78ra32.
98. Kunz L.I., Lapperre T.S., Snoeck-Stroband J.B., et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res 2011, 12:34.
99. Macredmond R.E., Greene C.M., Dorscheid D.R., et al. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res 2007, 8:84.
100. Sahlander K., Larsson K., Palmberg L. Daily exposure to dust alters innate immunity. PLoS One 2012, 7:e31646.
101. Lee S.W., Kim D.R., Kim T.J., et al. The association of down-regulated toll-like receptor 4 expression with airflow limitation and emphysema in smokers. Respir Res 2012, 13:106.
102. Speletas M., Merentiti V., Kostikas K., et al. Association of TLR4-T399I polymorphism with chronic obstructive pulmonary disease in smokers. Clin Dev Immunol 2009, 2009:260286.
103. Hoiby N., Ciofu O., Johansen H.K., et al. The clinical impact of bacterial biofilms. Int J Oral Sci 2011, 3:55-65.
104. Goldstein-Daruech N., Cope E.K., Zhao K.Q., et al. Tobacco smoke mediated induction of sinonasal microbial biofilms. PLoS One 2011, 6:e15700.
105. Starner T.D., Zhang N., Kim G., et al. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 2006, 174:213-220.
106. Hiltke T.J., Sethi S., Murphy T.F. Sequence stability of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae in the human respiratory tract. JInfect Dis 2002, 185:627-631.
107. Cholon D.M., Cutter D., Richardson S.K., et al. Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quantities of the HMW1 and HMW2 adhesins. Infect Immun 2008, 76(10):4463-4468.